SHANGHAI & GUANGZHOU, China, July 4, 2026
Sanyou Biopharmaceutical Co., Ltd. (Sanyou Bio) and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. (Baiyunshan Xihe) have entered into a strategic collaboration to accelerate the discovery and development of innovative radiopharmaceuticals and radiodiagnostic products for precision oncology. The partnership combines Sanyou Bio’s AI-powered drug discovery platforms with Baiyunshan Xihe’s comprehensive nuclear medicine manufacturing and clinical translation capabilities, creating an integrated innovation ecosystem that spans from target molecule discovery to clinical development. The collaboration aims to address growing global demand for highly targeted cancer diagnostics and therapies by leveraging artificial intelligence (AI), advanced antibody discovery, radionuclide production, and precision radiolabeling technologies. As radiopharmaceuticals continue to emerge as one of the fastest-growing areas in oncology, this alliance is expected to strengthen China’s innovation capabilities while accelerating the commercialization of next-generation theranostic solutions that combine disease diagnosis and targeted treatment.
AI-Driven Drug Discovery Meets Advanced Nuclear Medicine Platform
The strategic agreement integrates Sanyou Bio’s globally recognized AI-Super Trillion Antibody/Molecule Libraries (AI-STAL) and Sanyou AI-Drug Accelerator (SAI-DA) with Baiyunshan Xihe’s end-to-end nuclear medicine platform, creating a seamless workflow for radiopharmaceutical innovation. Through its proprietary AI technologies, Sanyou Bio will identify, screen, and optimize high-performance antibodies and targeting molecules designed for precision radiolabeling. Baiyunshan Xihe will then utilize its expertise in medical radionuclide production, Good Manufacturing Practice (GMP) manufacturing, radiolabeling, preclinical evaluation, and clinical translation to rapidly advance promising candidates toward clinical development.
By integrating these complementary capabilities, both organizations aim to significantly shorten the timeline from early target identification to radiopharmaceutical candidate selection while improving the precision, stability, and therapeutic potential of novel oncology products. This collaborative approach reflects the increasing role of artificial intelligence in biopharmaceutical research, enabling faster identification of highly specific molecular targets for precision cancer imaging and treatment.
Partnership Targets Next-Generation Theranostic Oncology Products
Advertisement
A major objective of the collaboration is the joint development of an internationally competitive portfolio of theranostic radiopharmaceuticals and innovative radiodiagnostic agents. Leveraging Baiyunshan Xihe’s established expertise in producing critical medical radionuclides—including Gallium-68, Zirconium-89, Copper-64, and Rhenium-186—the companies plan to develop highly targeted imaging and therapeutic products capable of improving cancer diagnosis and personalized treatment. The collaboration will establish a comprehensive “AI-driven molecular discovery – radionuclide labeling – clinical translation” development model, connecting upstream molecular innovation directly with downstream industrial manufacturing and regulatory development.
Beyond individual product development, the partnership also seeks to establish a broader collaborative ecosystem involving innovative drug research, nuclear medicine technologies, and clinical application, supporting China’s long-term ambition to become a global leader in radiopharmaceutical innovation. By combining intelligent molecular design with advanced radionuclide technologies, the alliance is expected to generate differentiated products capable of addressing critical unmet needs across multiple oncology indications.
Strategic Alliance Strengthens China’s Radiopharmaceutical Ecosystem
The partnership represents an important expansion of Sanyou Bio’s mission to accelerate global innovative drug development while strengthening Baiyunshan Xihe’s position as a leading enterprise within China’s nuclear medicine industry. With operations spanning Asia, North America, and Europe, Sanyou Bio has established collaborations with more than 2,000 pharmaceutical and biotechnology companies and has supported over 1,200 innovative drug discovery projects, demonstrating its extensive expertise in AI-enabled biologics development. Baiyunshan Xihe contributes comprehensive industrial capabilities spanning radionuclide production, standardized manufacturing, and clinical translation, creating a highly complementary partnership focused on next-generation precision medicine.
Together, both companies intend to explore additional collaborative opportunities beyond the current agreement, supporting the advancement of precision oncology, radiotheranostics, and AI-driven drug discovery. As investment and scientific interest continue to accelerate across the radiopharmaceutical sector, this strategic collaboration positions both organizations at the forefront of developing innovative nuclear medicine solutions capable of improving cancer diagnosis, treatment, and patient outcomes while contributing to the modernization of the global biopharmaceutical industry.
Source: Sanyou Bio press release
